1. Mercaptopurine-induced hepatoportal sclerosis in a patient with Crohn's disease.
- Author
-
Tuyama AC, Krakauer M, Alzaabi M, Fiel MI, Legnani P, and Schiano TD
- Subjects
- Ascites therapy, Humans, Hypertension, Portal pathology, Intestinal Obstruction therapy, Liver Function Tests, Male, Sclerosis chemically induced, Sclerosis pathology, Young Adult, Crohn Disease drug therapy, Hypertension, Portal chemically induced, Immunosuppressive Agents adverse effects, Mercaptopurine adverse effects, Portal System pathology
- Abstract
Thiopurines play a pivotal role in the management of inflammatory bowel disease. Azathioprine and mercaptopurine have been associated with a number of liver abnormalities, including hepatitis, veno-occlusive disease, nodular regenerative hyperplasia, and peliosis hepatitis. Patients treated with azathioprine and mercaptopurine have their liver chemistry tests routinely checked due to this potential for hepatotoxicity. Hepatoportal sclerosis is a cause of non-cirrhotic portal hypertension that is increasingly being recognized; its etiopathogenesis is not well defined. We present the first case report of mercaptopurine-induced hepatoportal sclerosis leading to non-cirrhotic portal hypertension in a patient with Crohn's disease. He had been treated with mercaptopurine for five years, and his liver chemistry tests were always within normal limits. This case underscores the potential serious liver adverse events that may arise silently and go undetected during treatment with mercaptopurine, and should alert clinicians as to the potential need to discontinue mercaptopurine in this setting., (Copyright © 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF